Please ensure Javascript is enabled for purposes of website accessibility

Cresco Labs Q4 Results: What You Need to Know

By Keith Speights - Mar 25, 2021 at 12:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The cannabis company's top line continued to improve in the fourth quarter.

Cresco Labs (CRLBF 1.56%) entered 2021 with a lot of momentum. Its shares soared 44% last year. But after rising over 70% year to date by early February, the stock has given up much of those gains in recent weeks.

The multi-state cannabis operator announced its fourth-quarter results before the market opened on Thursday. Cresco's shares fell close to 5% in early trading. Here are the highlights from the company's Q4 update.

Marijuana leaf over an American dollar bill.

Image source: Getty Images.

By the numbers

Cresco Labs reported revenue in the fourth quarter of $162.3 million, nearly tripling year over year and up 6% quarter over quarter. The result also narrowly beat the consensus analyst estimate of $161.4 million.

The company announced a net loss of $23.4 million in the fourth quarter. While this was better than the net loss of $45.2 million in the prior-year period, it reflected deterioration from the profit of $4.9 million posted in the third quarter of 2020. 

Cresco generated Q4 adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of $50 million. This result was a huge improvement of adjusted EBITDA of $2.9 million in the prior-year period and was 8% higher quarter over quarter. 

The cannabis operator ended the fourth quarter with cash and cash equivalents of $136.3 million. 

Behind the numbers

Cresco's year-over-year comparisons looked fantastic. However, the company completed the acquisition of Origin House in January 2020. Much of the improvement compared to the prior-year period came from this acquisition. Quarter-over-quarter comparisons reveal more about how Cresco actually performed in Q4.

The good news is that Cresco's sales grew solidly from the previous quarter. Even better, the company's gross profit margin improved.

Cresco reported a gross profit margin of 59% in Q4 compared to 55.2% in the third quarter. However, the increase wasn't quite as great on an operational basis. Factoring in various adjustments, including the net impact of the fair value of biological assets, the company's operating gross profit margin in Q4 was 54.5%, up from 52.6% in Q3.

While Cresco's adjusted EBITDA improved from the previous quarter, its bottom line worsened. A key reason behind this deterioration was that the company incurred much higher costs related to acquisitions, expansion, relaunch, and rebranding.

Looking ahead

Cresco Labs co-founder and CEO Charles Bachtell said: "In 2021, cultivation expansions are under way and we are executing accretive M&A [mergers and acquisitions] as we repeat our playbook in more states. Our best-in-class execution was on display in 2020 and it's what you can expect from Cresco Labs for years to come."

The company's acquisitions are sure to be a primary growth driver going forward. In January, Cresco announced plans to acquire Bluma Wellness to enter the medical cannabis market in Florida. It also completed the acquisitions of four Ohio medical cannabis dispensaries in February.

Cresco could soon have even better growth prospects. The state of New York appears headed toward legalizing recreational marijuana. Cresco already operates medical cannabis dispensaries in the state and would almost certainly quickly move into the recreational market as well.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cresco Labs Inc. Stock Quote
Cresco Labs Inc.
$3.90 (1.56%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.